Browse > Article
http://dx.doi.org/10.4333/KPS.2005.35.6.397

Effect of Probenecid on the Pharmacokinetic Behavior of Pranoprofen in Rats  

Li, Xiu-Guo (College of Pharmacy, Chosun University, Yanbian University Nursing College)
Piao, Yong-Ji (College of Pharmacy, Chosun University)
Choi, Jun-Shik (College of Pharmacy, Chosun University)
Publication Information
Journal of Pharmaceutical Investigation / v.35, no.6, 2005 , pp. 397-402 More about this Journal
Abstract
The purpose of this study was to investigate the effect of probencid on the pharmacokinetics of oral pranoprofen in rats. Pranoprofen (5 mg/kg) was coadministered with 5, 10 or 20 mg/kg of probenecid orally. Coadministration of probenecid significantly altered the pharmacokinetics of pranoprofen at 10 and 20 mg/kg. Compared with the control group, probenecid significantly (p<0.05) increased the absorption rate constant $(K_{a})$, the peak concentrations $(C_{max})$ and accordingly the area under the plasma concentration-time curve (AUC) of pranoprofen at the dose level of 10 mg/kg and 20 mg/kg of probenecid. The relative bioavailability (RB%) of pranoprofen was 1.64- to 1.82- fold increased. Furthermore, 10 and 20 mg/kg probenecid induced the decreased elimination constants $(K_{el})$ and the prolonged half-lives $(t_{1/2})$ of pranoprofen with significance (p<0.05). Coadministration of 10 and 20 mg/kg of probenecid lowered the excreted amounts of pranoprofen in the urine by 21.3-22.5% compared to the control. Overall, probenecid enhanced the bioavailability of pranoprofen and decreased its elimination rate to a greater degree at higher dose. Based on the effect of probenecid on the pharmacokinetic behavior of pranoprofen, the dosage regimen of pranoprofen should be taken into consideration when pranoprofen is administered with probenecid in the clinical setting to the patients especially with peptic ulcer or renal failure.
Keywords
Pranoprofen; Probenecid; Coadministration; Pharmacokinetics; Dosage regimen;
Citations & Related Records
연도 인용수 순위
  • Reference
1 T. Sekine, N. Watanabe, M. Hosoyarnada, Y. Kanai and H. Endou, Expression cloning and characterization of a novel multispecific organic anion transporter J. Biol. Chem., 272, 18526-18529 (1997)   DOI   ScienceOn
2 A.-B. Gutman and T.-F. Yu, Benemid (p-[di-n-propyl-sulfamyl]-benxoic acid) as uricosuric agent in chronic gouty arthritis, Trans. Assoc. Am. Physicians, 64, 279-288 (1951)
3 A.- B. Gutman, Uricosuric drugs, with special reference to probenecid and sulfmpyrazone, Adv. Pharmacol., 4, 91-142 (1966)   DOI
4 K.-H. Beyer, H.-F. Russo, E.-K. Tillson, A.-K. Miller, W.-F. Verwey and S.-R. Gass, 'Benemid,' p-(di-n-propylsulfamyl)-benzoic acid; its renal affinity and its elimination, Am. J. Physiol., 166, 625-640 (1951)
5 R.-C. Luders, M.-B. Maggio-Cavaliere, H. Egger, H.-T.-L. Chemiken, D.-B. Gum and O. Resnick, Disposition of piprofen, a new anti-inflammatory drug, Clin. Pharmacol. Ther., 21, 721-730 (1977)   DOI
6 Y.K atoh, Pranoprofen: In Drug disposition, Vol. 1, R. Katoh (Ed.), Seishi Shoin, Tokyo, pp. 223-229 (1984)
7 Y. Kato, N. Ariamand H. Nishimine, Studies on antiinflammatory agents XXXII. Absorption, excretion, distribution and metabolism of 2-(5h-[1]benzopyrano(2,3-b] pyridin-7-yl)propionic acid. (Y-8004) in rats and mice, Yakugaku Zasshi, 96, 819-826 (1976)   DOI
8 Z.-H. Israili, J.-M. Pereel, R.-F. Cunningham, P.-G. Dayton, T.-F. Yu, A.-B. Gutman, K.-R. Long, R.-C. Jr Long and J.-H. Goldstein, Metabolites of probenecid. Chemical, physical, and pharmacological studies, J. Med. Chem., 15, 709-713 (1972)   DOI
9 A.- M. Guarino, W.-D. Conway and H.-M. Fales, Mass spectral identification of probenecid metabolites in rat bile, Eur. J. Pharmacol., 8, 244-252 (1969)   DOI   ScienceOn
10 R.-F. Cunningham, Z.-H. Israili and P.-G. Dayton, Clinical pharmacokinetics of probenecid, Clin. Pharmacokinet., 6, 135-151 (1981)   DOI   ScienceOn
11 J.-M. PereI, R.-F. Cunningham, H.-M. Fales and P.-G. Dayton, Identification and renal excretion of probenecid metabolites in man, Life Sci. I., 9, 1337-1343 (1970)   DOI   ScienceOn
12 A.-M. Guarino and L.-S. Schanker, Biliary excretion of probenecid and its glucuronide, Pharmacal. Exp. Ther., 164, 387-395 (1968)
13 S.-P. Spina and E.-C. Jr Dillon, Effect of chronic probenecid therapy on cefazolin serum concentrations, Ann. Pharmacather., 37, 621-624 (2003)   DOI   ScienceOn
14 E.-S. Ho, D.-C. Lin, D.-B. Mendel and T. Cihlar, Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1, J. Am. Sac. Nephrol., 11, 383-393 (2000)
15 J.-B. Prtcihard and D.-S. Miller, Mechanisms mediating renal secretion of organic anions and cations, Physial. Rev., 73, 765-796 (1993)   DOI
16 R.-K. Verbeeck, Pharmacokinetic drug interactions with nonsteroidal anti-inflammatory drugs. Clin. Pharmacokinet., 19, 44-66 (1990)   DOI   ScienceOn
17 W.-P. Boger, F.-W. Pitts and M.-E. Gallagher, Benemid and carinamide: comparison of effect on para-aminosalicylic acid (PAS) plasma concentrations, J. Lab. Clin. Med., 36, 276-282 (1950)
18 Y. Uwai, M. Okuda, K. Takami, Y. Hashimoto and K. Inui, Functional characterization of the rat multispecific organic anion transporter OAT1 mediating basolateral uptake of anionic drugs in the kidney, FEBS. Lett., 438, 321-324 (1998)   DOI   ScienceOn
19 N. Yasui-Furukori, T. Uno, K. Sugawara and T. Tateishi, Different effects of three transporting inhibitors, veraparnil, cimetidine, and probenecid, on fexofenadine pharmacokinetics, Clin. Pharmacal. Ther., 77, 17-23 (2005)   DOI   ScienceOn
20 D.-R. Abernethy, D.-J. Greenblatt, B. Ameer and R.-I. Shader, Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation, J. Pharmacal. Exp. Ther., 234, 345-349 (1985)
21 D.-H. Chatfield and J.-N. Green, Disposition and metabolism of benoxaprofen in laboratory animal and man, Xenobiotica., 8, 133-144 (1978)   DOI   ScienceOn
22 A. Rubin, P. Warric, R.-L. Wolen, S.-M. Chemish, A.-S. Ridolfo and C.-M. Gruber Physiological disposition of fenoprofen in Man. III. Metabolism and protein binding of fenoprofen, J. Pharmacol. Exp. Ther., 183, 449-457 (1972)
23 L.-M. Fuccela, G.-C. Goldaniga, E. Moro, V. Tamassia, G.-P. Tosolini and G. Valzelli, Fate of analgesic and anti-inflammatory drug K4277 after oral administration to man, Dur. J.Clin.Pharmacol., 6, 256-260 (1973)   DOI   ScienceOn
24 M.-L. Rocci and W.-J. Juskko, LAGRAN program for area and moments in pharmacokinetic analysis, Comput. Programs Biomed., 16, 203-216 (1983)   DOI   ScienceOn
25 P.-G. Dayton, T.-F. Yu, W. Chen, L. Berger, L.-A. West and A.-B. Gutman, The physiological dispositon of probenecid, including renal clearance, in man, studied by an improved method for its estimation in biological material, J. Pharmacol. Exp. Ther., 140, 278-286 (1963)
26 T.-B. Tjandramaga, S.-A. Cucinell, Z.-H. Israili, J.-M. Perel, P.-G. Dayton, T.-F.Yu and A.-B. Gutman, Observations on the disposition of probenecid in patients receiving allopurinol, Pharmacology, 8, 259-272 (1972)
27 H.-L. McLeod, Clinically relevant drug-drug interactions in oncology. Br. J. Clin. Pharmacal., 45, 539-544 (1998)   DOI   ScienceOn
28 I. Yoshio, A. Iwata, M. Isobe, R. Takamatsu and M. Higashi, The pharmacokinetics of pranoprofen in humans, Yakugaku Zasshi, 110, 509-515 (1990)   DOI
29 K. Sagara, I. Yamada, Y. Matsuura, M. Kawata and M. Shibata, Gastrointestinal physiology-regulated dogs for bioavailability evaluation of an oral controlled-release dosage form composed of pulsatile release granules, Biol. Pharm. Bull., 19, 1184-1188 (1996)   DOI   ScienceOn
30 N. Baber, L. Halliday, R. Sibeon, T. Littler and M.-L. Orme, The interaction between indomethacin and probenecid. A clinical and pharmacokinetic study, Clin. Pharmacol. Ther., 24, 298-307 (1978)   DOI
31 W.-D. Conway and S. Melethil, Excretion of probenecid and its metabolites in bile and urine of rats, J. Pharm. Sci., 63, 1551-1554 (1974)   DOI
32 B. Bannwarth, F. Pehourcq, T. Schaeverbeke and J. Dehais, Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis, Clin. Pharmacakinet., 30, 194-210 (1996)   DOI   ScienceOn
33 T. Imai, T. Nomura and M. Otagiri, Probenecid-induced changes in the clearance of pranoprofen enantiomers, Chirality, 15, 318-323 (2003)   DOI   ScienceOn
34 A. Resetar, D. Minick and T. Spector, Glucuronidation of 3'-azido-3'-deoxythymidine catalyzed by human liver UDP-glucuronosyltransferase. Significance of nucleoside hydrophobicity and inhibition by xenobiotics, Biachem. Pharmacal., 42, 559-568 (1991)   DOI   ScienceOn